What Is LENZ Therapeutics, Inc. (LENZ) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on LENZ Therapeutics, Inc. at its current price of $4.99. The composite intrinsic value is estimated at $3.82 (-23.4% average return), with 7 models flagging overvaluation risk. Notably, EROIC sees the most upside at +68.1% (fair value: $8.39), while Sentiment SOTP is the most conservative at -83.9% ($0.81). The spread between these extremes — +152.0% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About LENZ?
11 of 13 models are currently active for LENZ. Of these, 4 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates LENZ's intrinsic value at $2.06, implying -58.8% downside from the current price. See which stocks rank higher →
How Does LENZ Rank in Biological Products, (No Diagnostic Substances)?
Among 134 Biological Products, (No Diagnostic Substances) stocks, LENZ ranks #59 by Quality of Company score. CirclFi's QOC score of 5.4/10 evaluates 32 fundamental signals. A score of 5.4 reflects mixed fundamentals.
See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →
LENZ Therapeutics, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is LENZ a Value Trap?
CirclFi's Value Trap algorithm assigns LENZ a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for LENZ Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, LENZ Therapeutics, Inc. is rated at 5.4/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +152.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every LENZ valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across LENZ's 11 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad